Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O75084

UPID:
FZD7_HUMAN

ALTERNATIVE NAMES:
FzE3

ALTERNATIVE UPACC:
O75084; O94816; Q53S59; Q96B74

BACKGROUND:
Frizzled-7, or FzE3, acts as a receptor in the Wnt signaling pathway, which is essential for cell development and differentiation. It is involved in various signaling mechanisms, including the beta-catenin pathway and interactions with G-proteins. Additionally, Frizzled-7 has been identified as a receptor for C.difficile toxin TcdB, highlighting its role in microbial infections.

THERAPEUTIC SIGNIFICANCE:
The exploration of Frizzled-7's functions offers promising avenues for therapeutic intervention. Given its involvement in critical signaling pathways and disease mechanisms, targeting Frizzled-7 could lead to innovative treatments for a range of conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.